Open AccessInterpreting discordance on dual-tracer positron emission tomography–computed tomography in the setting of metastatic neuroendocrine tumor: Detection of metachronous triple-negative breast carcinoma
Author(s) -
Ashwini Kalshetty,
Sandip Basu
Publication year - 2020
Publication title -
world journal of nuclear medicine
Language(s) - English
Resource type - Journals
eISSN - 1607-3312
pISSN - 1450-1147
DOI - 10.4103/wjnm.wjnm_15_20
Subject(s) - medicine , positron emission tomography , positron emission tomography computed tomography , neuroendocrine tumors , breast carcinoma , nuclear medicine , positron emission , breast cancer , radiology , neuroendocrine carcinoma , tomography , somatostatin receptor , pet ct , carcinoma , cancer , somatostatin , pathology
Second primary malignancies (SPMs) are known to be associated with neuroendocrine tumors (NETs). The association necessitates a careful assessment of the dual-tracer positron emission tomography–computed tomography (PET-CT) imaging findings to identify these malignancies earlier. Such early diagnosis can provide incremental benefit for screening these SPMs apart from their known applications in the management of NETs. A case of incidentally detected metachronous triple-negative breast carcinoma on dual-tracer PET-CT imaging is presented using 18fluoro-2-deoxy-D-glucose (FDG) and 68Ga-DOTATATE that showed a high uptake on FDG but no uptake on somatostatin receptor-based imaging.